Form 4: Artiva SVP Sells Shares to Cover Tax Obligations

SVP of Research and Development Heather Raymon sold 3,095 shares of Artiva Biotherapeutics to satisfy tax withholding requirements.

Summary

• Heather Raymon, SVP of Research and Development, sold 3,095 shares of common stock on May 19, 2026.
• The shares were sold at a weighted average price of $9.0078, with prices ranging from $8.7447 to $9.0104.
• The transaction was non-discretionary and executed under a mandatory sell-to-cover policy to meet tax obligations from vested restricted stock units.
• Following the sale, Raymon continues to hold a significant stake of 148,228 shares in the company.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral, administrative event that does not signal a change in management's outlook on the company's fundamental value.

Positives

• The sale was non-discretionary, meaning it does not reflect a lack of confidence in the company's prospects.
• The executive maintains a substantial ownership position of 148,228 shares.
• The transaction demonstrates a structured approach to managing executive compensation and tax compliance.

Negatives

• The sale results in a minor reduction of the executive's direct equity holdings.

Risks

• Market volatility may impact the execution price of future automatic sell-to-cover transactions.

Future Outlook

No specific forward-looking guidance or strategic updates were provided in this ownership report.

Management Comments

• The Issuer has adopted a 'sell-to-cover' policy to satisfy the tax withholding obligations of the Reporting Person.
• Such sales were automatic and not at the discretion of the Reporting Person.

Industry Context

StockSavvy.ai notes that 'sell-to-cover' transactions are a routine administrative occurrence in the biotechnology sector, where equity-based compensation is a primary component of executive pay and retention strategies.

Comparison to Industry Standards

• The use of sell-to-cover policies is consistent with practices at other clinical-stage biotech firms such as Fate Therapeutics and Nkarta.
• The transparency regarding the price range ($8.7447 to $9.0104) aligns with SEC best practices for reporting weighted average sales in Form 4 filings.

Corporate Governance

Related Party Transactions

• The reporting person, an officer of the company, sold shares to satisfy tax obligations related to equity compensation granted by the issuer.

Stakeholder Impact

• Minimal impact on shareholders as the sale was small relative to the executive's total holdings and the company's overall market capitalization.

Next Steps

• Monitor for future Form 4 filings to track insider sentiment and ownership trends.
• Await clinical data updates or quarterly financial results for broader business context.

Key Dates

Recommendation

The transaction is a routine tax-related sale and does not provide a catalyst for changing the investment thesis or the current valuation of the stock.

Keywords

Artiva Biotherapeutics, ARTV, Insider Selling, Form 4, Executive Compensation, Biotechnology, Tax Withholding, Heather Raymon